A clinical study of rGDF11
Latest Information Update: 04 Dec 2020
At a glance
- Drugs Recombinant growth differentiation factor 11-Elevian (Primary)
- Indications Obesity; Stroke
- Focus Adverse reactions
- 04 Dec 2020 New trial record
- 24 Nov 2020 According to an Elevian media release, the company announced the closing of a $15 million equity financing and proceeds from this equity financing will enable company to initiate this study.